{\rtf1\ansi\deff3\adeflang1025
{\fonttbl{\f0\froman\fprq2\fcharset0 Times New Roman;}{\f1\froman\fprq2\fcharset2 Symbol;}{\f2\fswiss\fprq2\fcharset0 Arial;}{\f3\froman\fprq2\fcharset0 Liberation Serif{\*\falt Times New Roman};}{\f4\fswiss\fprq2\fcharset0 Liberation Sans{\*\falt Arial};}{\f5\froman\fprq2\fcharset0 Times New Roman;}{\f6\fnil\fprq2\fcharset2 Symbol;}{\f7\fnil\fprq0\fcharset0 OpenSymbol{\*\falt Arial Unicode MS};}{\f8\fswiss\fprq2\fcharset0 Arial;}{\f9\fnil\fprq2\fcharset0 DejaVu Sans;}{\f10\fnil\fprq2\fcharset0 Lohit Hindi;}{\f11\fnil\fprq0\fcharset0 Lohit Hindi;}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red68\green68\blue68;}
{\stylesheet{\s0\snext0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057 Normal;}
{\s1\sbasedon29\snext30\ilvl0\outlinelevel0\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb227\sa113\keepn\caps\b\dbch\af9\dbch\af10\afs28\loch\f5\fs22 Heading 1;}
{\s2\sbasedon29\snext30\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22 Heading 2;}
{\s3\sbasedon29\snext30\ilvl2\outlinelevel2\sb140\sa120\keepn\cf15\b\dbch\af9\dbch\af10\afs28\ab\loch\f4\fs28 Heading 3;}
{\*\cs15\snext15\afs18\fs18 Comment Reference;}
{\*\cs16\snext16\i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22 WW8Num2z0;}
{\*\cs17\snext17\dbch\af7\loch\f7 WW8Num2z1;}
{\*\cs18\snext18 WW8Num2z2;}
{\*\cs19\snext19 WW8Num2z3;}
{\*\cs20\snext20 WW8Num2z4;}
{\*\cs21\snext21 WW8Num2z5;}
{\*\cs22\snext22 WW8Num2z6;}
{\*\cs23\snext23 WW8Num2z7;}
{\*\cs24\snext24 WW8Num2z8;}
{\*\cs25\snext25 WW-Default Paragraph Font1;}
{\*\cs26\sbasedon25\snext26 Internet Link;}
{\*\cs27\snext27 Numbering Symbols;}
{\*\cs28\snext28 Line Numbering;}
{\s29\sbasedon0\snext30\sb240\sa120\keepn\dbch\af9\dbch\af10\afs28\loch\f4\fs28 Heading;}
{\s30\sbasedon0\snext30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22 Text Body;}
{\s31\sbasedon30\snext31\sl480\slmult1\qj\sb0\sa113\dbch\af11\loch\f5\fs22 List;}
{\s32\sbasedon0\snext32\sb120\sa120\noline\i\dbch\af11\afs24\ai\fs24 Caption;}
{\s33\sbasedon0\snext33\noline\dbch\af11 Index;}
{\s34\sbasedon0\snext34\noline Table Contents;}
{\s35\sbasedon33\snext35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22 Bibliography 1;}
{\s36\sbasedon0\snext36\li567\ri567\lin567\rin567\fi0\sb0\sa283 Quotations;}
{\s37\sbasedon29\snext30\qc\sb240\sa120\keepn\b\dbch\af9\dbch\af10\afs56\ab\loch\f4\fs56 Title;}
{\s38\sbasedon29\snext30\qc\sb60\sa120\keepn\dbch\af9\dbch\af10\afs36\loch\f4\fs36 Subtitle;}
{\s39\sbasedon0\snext39\tqc\tx4819\tqr\tx9638\noline Footer;}
{\s40\sbasedon34\snext40\noline Table Heading;}
{\s41\sbasedon0\snext41\noline Header;}
}{\*\listtable{\list\listtemplateid1
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-432\li432}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-576\li576}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-720\li720}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-864\li864}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1008\li1008}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1152\li1152}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1296\li1296}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1440\li1440}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1584\li1584}\listid1}
{\list\listtemplateid2
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\i0\b\highlight7\dbch\af7\afs22\ai0\ab\fi-432\li432}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\dbch\af7\fi-576\li576}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-720\li720}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-864\li864}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1008\li1008}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1152\li1152}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1296\li1296}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1440\li1440}
{\listlevel\levelnfc255\leveljc0\levelstartat1\levelfollow2{\leveltext \'00;}{\levelnumbers;}\fi-1584\li1584}\listid2}
{\list\listtemplateid3
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'00.;}{\levelnumbers\'01;}\fi-360\li720}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'01.;}{\levelnumbers\'01;}\fi-360\li1080}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'03(\'02);}{\levelnumbers\'02;}\fi-360\li1440}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'03.;}{\levelnumbers\'01;}\fi-360\li1800}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'04.;}{\levelnumbers\'01;}\fi-360\li2160}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'05.;}{\levelnumbers\'01;}\fi-360\li2520}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'06.;}{\levelnumbers\'01;}\fi-360\li2880}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'07.;}{\levelnumbers\'01;}\fi-360\li3240}
{\listlevel\levelnfc0\leveljc0\levelstartat1\levelfollow0{\leveltext \'02\'08.;}{\levelnumbers\'01;}\fi-360\li3600}\listid3}
}{\listoverridetable{\listoverride\listid1\listoverridecount0\ls1}{\listoverride\listid2\listoverridecount0\ls2}{\listoverride\listid3\listoverridecount0\ls3}}{\*\generator LibreOffice/5.1.6.2$Linux_X86_64 LibreOffice_project/10m0$Build-2}{\info{\author Rudolf Cardinal}{\creatim\yr2014\mo3\dy25\hr20\min13}{\author Rudolf Cardinal}{\revtim\yr2015\mo7\dy14\hr10\min36}{\printim\yr2014\mo3\dy28\hr14\min18}}\deftab720
\viewscale140
{\*\pgdsctbl
{\pgdsc0\pgdscuse451\pgwsxn11906\pghsxn16838\marglsxn1440\margrsxn1440\margtsxn1976\headery1440\margbsxn1440{\header\pard\plain \s41\noline\qr{\afs22\loch\f6\fs22\loch\f7\rtlch \ltrch\fs22\loch\f5
{\field{\*\fldinst  PAGE }{\fldrslt 19}}}
\par }\pgdscnxt0 Default Style;}}
\formshade{\*\pgdscno0}\paperh16838\paperw11906\margl1440\margr1440\margt1440\margb1440\sectd\sbknone\sectunlocked1\pgndec\pgwsxn11906\pghsxn16838\marglsxn1440\margrsxn1440\margtsxn1976\headery1440\margbsxn1440{\header\pard\plain \s41\noline\qr{\afs22\rtlch \ltrch\fs22\loch\f5
{\field{\*\fldinst  PAGE }{\fldrslt 19}}}
\par }\linemod5\linex283\linecont\ftnbj\ftnstart1\ftnrstcont\ftnnar\aenddoc\aftnrstcont\aftnstart1\aftnnrlc
{\*\ftnsep\chftnsep}\pgndec\pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\cf1\b\afs22\rtlch \ltrch\loch\fs22
Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia }{\cf1\b\afs22\rtlch \ltrch\loch\fs22
assessed using a mental health case register}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\cf1\b\afs22\rtlch \ltrch\loch\fs22

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
Rudolf N. Cardinal }{\rtlch \ltrch\loch
(1, 2, *)}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
George Savulich }{\rtlch \ltrch\loch
(1)}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
Louisa }{\b\ab\rtlch \ltrch\loch
M. }{\b\ab\rtlch \ltrch\loch
Mann }{\rtlch \ltrch\loch
(2)}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
Emilio Fern\u225\'e1ndez-Egea }{\rtlch \ltrch\loch
(1, }{\rtlch \ltrch\loch
2}{\rtlch \ltrch\loch
)}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain  1.\tab}\ilvl0\ls3 \li720\ri0\lin720\rin0\fi-360\sl480\slmult1{\rtlch \ltrch\loch
Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, UK.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain  2.\tab}\ilvl0\ls3 \li720\ri0\lin720\rin0\fi-360\sl480\slmult1{\rtlch \ltrch\loch
Cambridgeshire and Peterborough NHS Foundation Trust, Elizabeth House, Fulbourn Hospital, Fulbourn, Cambridge CB21 5EF, UK.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\li0\ri0\lin0\rin0\fi0\rtlch \ltrch\loch

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\rtlch \ltrch\loch
(*) Corresponding author. Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, Sir William Hardy Building, Downing Site, Cambridge CB2 3EB, UK. Tel. }{\rtlch \ltrch\loch
+44 (0)1223 }{\rtlch \ltrch\loch
330272. Fax }{\rtlch \ltrch\loch
+44 (0)}{\rtlch \ltrch\loch
7092}{\rtlch \ltrch\loch
 }{\rtlch \ltrch\loch
340645. E-mail rudolf@pobox.com.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\cf0\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22\lang1033

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\cf0\i\b0\afs22\ai\ab0\rtlch \ltrch\loch\fs22\lang1033
Running title:}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\cf0\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22\lang1033
\tab Drug treatments and admissions for schizophrenia}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\cf0\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22\lang1033

\par \pard\plain \s1\ilvl0\outlinelevel0\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb227\sa113\keepn\caps\b\dbch\af9\dbch\af10\afs28\loch\f5\fs22\pagebb{\listtext\pard\plain \tab}\ls1 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\cf1\b\afs22\rtlch \ltrch\loch\fs22
ABSTRACT}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
Background: }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22\lang1033
The impact of psychotropic drug choice upon admissions for schizophrenia is }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22\lang1033
not well}{\b0\afs22\ab0\rtlch \ltrch\loch\fs22\lang1033
 understood. }{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
Objective}{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
: }{\afs22\rtlch \ltrch\loch\fs22\lang1033
To examine the association between antipsychotic/antidepressant use and time in hospital for patients with schizophrenia. }{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
Method}{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
s}{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
: }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22\lang1033
We conducted an o}{\afs22\rtlch \ltrch\loch\fs22\lang1033
bservational study, using 8 years\u8217\'92 admission records and electronically generated drug histories }{\afs22\rtlch \ltrch\loch\fs22\lang1033
from an institution providing secondary mental health care in Cambridgeshire, UK, covering the period 2005\u8211\'962012 inclusive}{\afs22\rtlch \ltrch\loch\fs22\lang1033
. }{\afs22\rtlch \ltrch\loch\fs22\lang1033
Patients with a coded ICD-10 diagnosis of schizophrenia were selected. The primary outcome measure was the time spent as an inpatient in a psychiatric unit. Antipsychotic and antidepressant drugs used by at least 5% of patients overall were examined for associations with admissions. }{\afs22\rtlch \ltrch\loch\fs22\lang1033
Periods before and after drug commencement were compared for patients having pre-drug admissions, }{\afs22\rtlch \ltrch\loch\fs22\lang1033
in mirror-image analyses }{\afs22\rtlch \ltrch\loch\fs22\lang1033
correcting for overall admission rates. Drug use in one }{\afs22\rtlch \ltrch\loch\fs22\lang1033
six-month }{\afs22\rtlch \ltrch\loch\fs22\lang1033
calendar period was used to predict admissions in the next period, across all patients, }{\afs22\rtlch \ltrch\loch\fs22\lang1033
in a regression analysis accounting for the effects of all other drugs studied and for }{\afs22\rtlch \ltrch\loch\fs22\lang1033
time}{\afs22\rtlch \ltrch\loch\fs22\lang1033
. }{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
Results: }{\afs22\rtlch \ltrch\loch\fs22\lang1033
In mirror-image analyses, sulpiride, aripiprazole, clozapine, and olanzapine were associated with fewer subsequent admission-days. In regression analyses, sulpiride, mirtazapine, }{\afs22\rtlch \ltrch\loch\fs22\lang1033
venlafaxine,}{\afs22\rtlch \ltrch\loch\fs22\lang1033
 and clozapine\u8211\'96aripiprazole and clozapine\u8211\'96amisulpride combinations were associated with fewer subsequent admission-days. }{\b\afs22\ab\rtlch \ltrch\loch\fs22\lang1033
Conclusions: }{\afs22\rtlch \ltrch\loch\fs22\lang1033
Use of these drugs were associated with fewer days in hospital. }{\afs22\rtlch \ltrch\loch\fs22\lang1033
Causation is not implied and these findings require confirmation by randomized controlled trials.}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1\cf0\i\b\afs22\ai\ab\rtlch \ltrch\loch\fs22\lang1033\loch\f5

\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1{\cf0\i\b\afs22\ai\ab\rtlch \ltrch\loch\fs22\lang1033\loch\f5
Keywords:}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1{\cf0\i\afs22\ai\rtlch \ltrch\loch\fs22\lang1033\loch\f5
\tab antidepressants}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1{\cf0\i\afs22\ai\rtlch \ltrch\loch\fs22\lang1033\loch\f5
\tab antipsychotics}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1{\cf0\i\afs22\ai\rtlch \ltrch\loch\fs22\lang1033\loch\f5
\tab epidemiology}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1{\cf0\i\afs22\ai\rtlch \ltrch\loch\fs22\lang1033\loch\f5
\tab inpatient treatment}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1{\cf0\i\afs22\ai\rtlch \ltrch\loch\fs22\lang1033\loch\f5
\tab psychotic disorders}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1{\cf0\i\afs22\ai\rtlch \ltrch\loch\fs22\lang1033\loch\f5
\tab schizophrenia}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057\sl480\slmult1\cf0\i\afs22\ai\rtlch \ltrch\loch\fs22\lang1033\loch\f5

\par \pard\plain \s1\ilvl0\outlinelevel0\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb227\sa113\keepn\caps\b\dbch\af9\dbch\af10\afs28\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\cf1\b\afs22\rtlch \ltrch\loch\fs22
INTRODUCTION}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
Admissions to psychiatric inpatient units are a }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
potential }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
marker of disease }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
severity }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
in schizophrenia, }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
and}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 a }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
burden }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
on}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 the individual. }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
UK guidelines }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
emphasize }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
avoiding admission, }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
and}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 antipsychotic }{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
drugs}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 as the mainstay of treatment}{\scaps0\caps0\cf1\super\i0\ulnone\ulc0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
1}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
. Randomized}{\scaps0\caps0\cf1\super\i0\ulnone\ulc0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
2,3}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 and non-randomized}{\scaps0\caps0\cf1\super\i0\ulnone\ulc0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
4}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\rtlch \ltrch\loch
\u8211\'968}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 studies have examined the effect of some antipsychotic}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
s}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 on admissions. However, information on admission reduction is sparser across the full range of drugs used clinical}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
ly}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
, and in relation to multi}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
ple}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
-drug strategies such as clozapine augmentation}{\scaps0\caps0\cf1\super\i0\ulnone\ulc0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
9,10}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 and antidepressant addition}{\scaps0\caps0\cf1\super\i0\ulnone\ulc0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
11}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
W}{\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
e sought to examine the impact of individual antipsychotic drugs but also of commonly prescribed antidepressants and clozapine augmentation strategies on hospital admissions in patients with schizophrenia, using a naturalistic clinical sample across an 8-year period.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{{\*\bkmkend _ENREF_6}{\*\bkmkend __DdeLink__1558_10158622931}\cf1\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
W}{{\*\bkmkstart _ENREF_6}{\*\bkmkstart _ENREF_13}{\*\bkmkstart __DdeLink__1491_1015862293}{\*\bkmkstart __DdeLink__1484_1015862293}{\*\bkmkstart __DdeLink__1486_1015862293}{\*\bkmkstart __DdeLink__499_618207270}{\*\bkmkstart __DdeLink__1482_1015862293}{\*\bkmkstart __DdeLink__489_618207270}{\*\bkmkstart __DdeLink__2324_273168210}{\*\bkmkstart __DdeLink__1009_1529088695}{\*\bkmkstart __DdeLink__487_618207270}{\*\bkmkstart __DdeLink__501_618207270}{\*\bkmkstart __DdeLink__1558_10158622931}{\*\bkmkstart __DdeLink__9900_446909264}{\*\bkmkstart __DdeLink__2057_2003706413}{\*\bkmkstart __DdeLink__1506_1015862293}{\*\bkmkstart __DdeLink__1500_1015862293}{\*\bkmkstart __DdeLink__1508_1015862293}{\*\bkmkstart __DdeLink__1502_1015862293}{\*\bkmkstart __DdeLink__1504_1015862293}{\*\bkmkstart __DdeLink__1498_1015862293}{\*\bkmkstart __DdeLink__1477_10158622931}{\*\bkmkstart __DdeLink__1474_10158622931}{\*\bkmkstart __DdeLink__3451_1404418203}\cf1\afs22\rtlch \ltrch\loch\fs22
e examined the anonymised electronic records of patients with schizophrenia within an NHS Trust. We investigated the associations between the antipsychotics/antidepressants }{\cf1\afs22\rtlch \ltrch\loch\fs22
use }{\cf1\afs22\rtlch \ltrch\loch\fs22
and time spent in hospital. }{\cf1\afs22\rtlch \ltrch\loch\fs22
To examine the impact of drug initiation on patients with relatively severe schizophrenia, w}{\cf1\afs22\rtlch \ltrch\loch\fs22
e conducted mirror-image analyses }{\cf1\afs22\rtlch \ltrch\loch\fs22
examining }{\cf1\afs22\rtlch \ltrch\loch\fs22
the duration of admissions before and after }{\cf1\afs22\rtlch \ltrch\loch\fs22
drug }{\cf1\afs22\rtlch \ltrch\loch\fs22
initiation, in all patients who had been admitted during the pre-drug period, controlling for overall changes in admission rate. }{\cf1\afs22\rtlch \ltrch\loch\fs22
To account for the use of more than one drug and to address additional confounds, w}{\cf1\afs22\rtlch \ltrch\loch\fs22
e }{\cf1\afs22\rtlch \ltrch\loch\fs22
also }{\cf1\afs22\rtlch \ltrch\loch\fs22
conducted regression analyses to model admission durations by drug prescription, across all patients and drugs.}
\par \pard\plain \s1\ilvl0\outlinelevel0\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb227\sa113\keepn\caps\b\dbch\af9\dbch\af10\afs28\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\rtlch \ltrch\loch
METHODS}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\rtlch \ltrch\loch\fs22
Data sources}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
Cambridgeshire and Peterborough NHS Foundation Trust (CPFT) }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
provides }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
secondary }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
mental health }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
care }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
to}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
 Cambridgeshire }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
(}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
population }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
~}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
800,000}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
)}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\ai0\rtlch \ltrch\loch\fs22
12}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
. }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
Its e}{\afs22\rtlch \ltrch\loch\fs22
lectronic records }{\afs22\rtlch \ltrch\loch\fs22
from 2005\u8211\'962012 }{\afs22\rtlch \ltrch\loch\fs22
were de-identified using CRIS}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
13}{\afs22\rtlch \ltrch\loch\fs22
 into a research database (UK }{\afs22\rtlch \ltrch\loch\fs22
NHS }{\afs22\rtlch \ltrch\loch\fs22
National Research Ethics Service reference 12/EE/0407).}{\b\afs22\ab\rtlch \ltrch\loch\fs22
 }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
Unstructured text}{\afs22\rtlch \ltrch\loch\fs22
, such as letters and discharge summaries, were searched using GATE}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
14}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
natural language processing (NLP) software }{\afs22\rtlch \ltrch\loch\fs22
for drug names and common misspellings in a grammatical context indicating }{\afs22\rtlch \ltrch\loch\fs22
current }{\afs22\rtlch \ltrch\loch\fs22
use, generating drug histor}{\afs22\rtlch \ltrch\loch\fs22
ies}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
15}{\afs22\rtlch \ltrch\loch\fs22
. The principal }{\afs22\rtlch \ltrch\loch\fs22
data }{\afs22\rtlch \ltrch\loch\fs22
sources were electronic }{\afs22\rtlch \ltrch\loch\fs22
psychiatric }{\afs22\rtlch \ltrch\loch\fs22
admission logs, }{\afs22\rtlch \ltrch\loch\fs22
autogenerated }{\afs22\rtlch \ltrch\loch\fs22
drug histories, and coded ICD-10 diagnoses}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
16}{\afs22\rtlch \ltrch\loch\fs22
.}{{\*\bkmkend __DdeLink__3451_1404418203}\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
Diagnoses were assigned by clinicians (though sometimes subsequently recorded in structured fields by }{\afs22\rtlch \ltrch\loch\fs22
administrative staff}{\afs22\rtlch \ltrch\loch\fs22
) and clinicians were the predominant authors of free-text documents referencing medication use. }{\afs22\rtlch \ltrch\loch\fs22
A}{\afs22\rtlch \ltrch\loch\fs22
dmission and discharge information was typically recorded by administrative staff. }{\afs22\rtlch \ltrch\loch\fs22
No electronic prescribing system was in use, necessitating the use of computer-generated drug histories.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\b0\afs22\ab0\rtlch \ltrch\loch\fs22
Inclusion and exclusion criteria and measures of illness duration}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
We studied patients for whom an ICD-10 diagnosis within \u8220\'93F20\u8221\'94 (schizophrenia) had been recorded in a structured \u8220\'93diagnosis\u8221\'94 field at some point. The first such entry was taken }{\afs22\rtlch \ltrch\loch\fs22
as}{\afs22\rtlch \ltrch\loch\fs22
 the date of diagnosis of schizophrenia. In some cases, electronic diagnoses had been entered }{\afs22\rtlch \ltrch\loch\fs22
with }{\afs22\rtlch \ltrch\loch\fs22
retrospective }{\afs22\rtlch \ltrch\loch\fs22
dates}{\afs22\rtlch \ltrch\loch\fs22
. For patients who had died, time after death was excluded.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\rtlch \ltrch\loch\fs22
Dependent variables}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
The primary dependent variable was the number of days spent as an inpatient }{\afs22\rtlch \ltrch\loch\fs22
(}{\afs22\rtlch \ltrch\loch\fs22
discharge date minus admission date, summed across admissions}{\afs22\rtlch \ltrch\loch\fs22
)}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\b0\afs22\ab0\rtlch \ltrch\loch\fs22
Drugs analysed}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
We searched for first-generation and second-generation antipsychotics (}{\afs22\rtlch \ltrch\loch\fs22
FGAs, }{\afs22\rtlch \ltrch\loch\fs22
SGAs), plus all UK-licensed antidepressants. We restricted further analyses to drugs used by }{{\*\bkmkstart __DdeLink__678_595472171}\afs22\rtlch \ltrch\loch\fs22
\u8805\'3f5%}{{\*\bkmkend __DdeLink__678_595472171}\afs22\rtlch \ltrch\loch\fs22
 of patients.}{\i\b\afs22\ab\rtlch \ltrch\loch\fs22
 }{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
In regression analyses, to reduce confounding from co-prescription, we also included benzodiazepines/Z-drugs and mood stabilizers used by \u8805\'3f5% of patients. }{\afs22\rtlch \ltrch\loch\fs22
We calculated a median dose }{\afs22\rtlch \ltrch\loch\fs22
(as the median of all patients\u8217\'92 median daily doses).}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\rtlch \ltrch\loch\fs22
Precision and recall}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
Precision and recall were measured for clozapine (see }{\b\afs22\ab\rtlch \ltrch\loch\fs22
Supplementary Methods}{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
).}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\ai\rtlch \ltrch\loch\fs22
Mirror-image comparisons of admission rates during pre-drug and post-drug periods}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
W}{\afs22\rtlch \ltrch\loch\fs22
e calculated a pre- versus post-drug comparison using a mirror-image design}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
17}{\afs22\rtlch \ltrch\loch\fs22
 }{\b\afs22\ab\rtlch \ltrch\loch\fs22
(Figure 1)}{\afs22\rtlch \ltrch\loch\fs22
, for all }{\afs22\rtlch \ltrch\loch\fs22
drugs studied}{{\*\bkmkend __DdeLink__1477_10158622931}{\*\bkmkend __DdeLink__1474_10158622931}\afs22\rtlch \ltrch\loch\fs22
. }{\afs22\rtlch \ltrch\loch\fs22
For each patient, w}{\afs22\rtlch \ltrch\loch\fs22
e calculated a start date }{\afs22\rtlch \ltrch\loch\fs22
(}{\afs22\rtlch \ltrch\loch\fs22
the study start date or their first diagnosis of schizophrenia, whichever was later}{\afs22\rtlch \ltrch\loch\fs22
), an end date (}{\afs22\rtlch \ltrch\loch\fs22
the study end date or their date of death if they had die}{\cs15\afs18\fs18\afs22\rtlch \ltrch\loch\fs22
d}{\afs22\rtlch \ltrch\loch\fs22
, whichever was earlier}{\afs22\rtlch \ltrch\loch\fs22
), }{\afs22\rtlch \ltrch\loch\fs22
and }{\afs22\rtlch \ltrch\loch\fs22
the \u8220\'93first use\u8221\'94 date for }{\afs22\rtlch \ltrch\loch\fs22
each }{\afs22\rtlch \ltrch\loch\fs22
drug. Because of potential temporal imprecision in the exact }{\afs22\rtlch \ltrch\loch\fs22
first-use}{\afs22\rtlch \ltrch\loch\fs22
 date, and to reduce the impact of regression to the mean, we excluded a central period C either side of the }{\afs22\rtlch \ltrch\loch\fs22
first-use}{\afs22\rtlch \ltrch\loch\fs22
 date (giving a central gap of 2C), and then looked at a mirrored period M either side of that central gap (}{\b\afs22\ab\rtlch \ltrch\loch\fs22
Figure 1}{\afs22\rtlch \ltrch\loch\fs22
). We examined a temporally narrow period (M = 1 year) and a temporally broader period (M = 2 years).}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
We excluded any patient }{\afs22\rtlch \ltrch\loch\fs22
if their }{\afs22\rtlch \ltrch\loch\fs22
mirror period }{\afs22\rtlch \ltrch\loch\fs22
was not within }{\afs22\rtlch \ltrch\loch\fs22
the }{\afs22\rtlch \ltrch\loch\fs22
start\u8211\'96end date range }{\afs22\rtlch \ltrch\loch\fs22
(i.e. if they had taken the drug soon after diagnosis, lack}{\afs22\rtlch \ltrch\loch\fs22
ing}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
sufficient}{\afs22\rtlch \ltrch\loch\fs22
 pre-drug }{\afs22\rtlch \ltrch\loch\fs22
time}{\afs22\rtlch \ltrch\loch\fs22
, or if their first-}{\afs22\rtlch \ltrch\loch\fs22
use date}{\afs22\rtlch \ltrch\loch\fs22
 was close to their end date, }{\afs22\rtlch \ltrch\loch\fs22
lacking }{\afs22\rtlch \ltrch\loch\fs22
sufficient}{\afs22\rtlch \ltrch\loch\fs22
 post-drug }{\afs22\rtlch \ltrch\loch\fs22
time}{\afs22\rtlch \ltrch\loch\fs22
). Thus, as far as could be established electronically, all patients in this analysis had a period free of the drug of interest, commencement of the drug in question, and a period of equal duration subsequently. We calculated the number of admission days in the}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
M}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 and M}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
periods}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
As our interest was in the potential impact of treatments upon admissions, and the inclusion of large numbers of relatively well patients (having few admissions) would reduce power, we excluded all patients with zero adm}{\afs22\rtlch \ltrch\loch\fs22
ission days in M}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 before comparing pre- and post-drug periods. Therefore, in this analysis we studied }{\afs22\rtlch \ltrch\loch\fs22
relatively unwell }{\afs22\rtlch \ltrch\loch\fs22
patients.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
O}{\afs22\rtlch \ltrch\loch\fs22
verall admission rates decreased over time. If this effect were not itself due to treatments, then it would bias results in favour of treatments. We therefore corrected for overall admission rates. For each mirror period (M}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
and M}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
), in addition to the per-subject admission rates }{\i\afs22\ai\rtlch \ltrch\loch\fs22
x}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 and }{\i\afs22\ai\rtlch \ltrch\loch\fs22
x}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{{\*\bkmkend __DdeLink__1504_1015862293}{\*\bkmkend __DdeLink__1498_1015862293}\afs22\rtlch \ltrch\loch\fs22
, we }{{\*\bkmkend __DdeLink__1502_1015862293}\afs22\rtlch \ltrch\loch\fs22
calculated the mean admission rate for all patients, }{\i\afs22\ai\rtlch \ltrch\loch\fs22
\u181\'b5}{{\*\bkmkend __DdeLink__1508_1015862293}\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 and }{\i\afs22\ai\rtlch \ltrch\loch\fs22
\u181\'b5}{{\*\bkmkend __DdeLink__1500_1015862293}\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
. Then, instead of analysing (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
x}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
 \u8211\'96 }{\i\afs22\ai\rtlch \ltrch\loch\fs22
x}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
)}{{\*\bkmkend __DdeLink__1506_1015862293}\afs22\rtlch \ltrch\loch\fs22
, we analysed }{\afs22\rtlch \ltrch\loch\fs22
and report }{\afs22\rtlch \ltrch\loch\fs22
[}{\afs22\rtlch \ltrch\loch\fs22
(}{\i\afs22\ai\rtlch \ltrch\loch\fs22
x}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
 \u8211\'96 }{\i\afs22\ai\rtlch \ltrch\loch\fs22
\u181\'b5}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
) \u8211\'96 (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
x}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 \u8211\'96 }{\i\afs22\ai\rtlch \ltrch\loch\fs22
\u181\'b5}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
)}{\afs22\rtlch \ltrch\loch\fs22
]}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\ai\rtlch \ltrch\loch\fs22
Regression analysis}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
All patients were analysed simultaneously }{\afs22\rtlch \ltrch\loch\fs22
via a mixed-effects general linear model}{\afs22\rtlch \ltrch\loch\fs22
. }{\afs22\rtlch \ltrch\loch\fs22
We divided }{\afs22\rtlch \ltrch\loch\fs22
time }{\afs22\rtlch \ltrch\loch\fs22
into }{\afs22\rtlch \ltrch\loch\fs22
6-month }{\afs22\rtlch \ltrch\loch\fs22
periods. The dependent variable was the number of inpatient-days per patient per period (re-expressed as admission-days per year). }{\afs22\rtlch \ltrch\loch\fs22
The predictors were: }{\afs22\rtlch \ltrch\loch\fs22
subject (a random factor), calendar period (to control for overall changes in admission rates; linear fixed effect), sex (factorial fixed effect), }{\afs22\rtlch \ltrch\loch\fs22
time since diagnosis }{\afs22\rtlch \ltrch\loch\fs22
(from the first recorded diagnosis of schizophrenia to the mid-point of the period in question, }{\afs22\rtlch \ltrch\loch\fs22
as an estimate of illness duration}{\afs22\rtlch \ltrch\loch\fs22
; linear fixed effect), }{\afs22\rtlch \ltrch\loch\fs22
age (though this correlates with time since diagnosis; }{\afs22\rtlch \ltrch\loch\fs22
linear fixed effect}{\afs22\rtlch \ltrch\loch\fs22
), }{\afs22\rtlch \ltrch\loch\fs22
and whether the patient was or was not documented as taking each drug in the immediately }{\i\afs22\ai\rtlch \ltrch\loch\fs22
preceding}{\afs22\rtlch \ltrch\loch\fs22
 period (factorial fixed effects; data from the very first period were therefore not }{\afs22\rtlch \ltrch\loch\fs22
modelled}{\afs22\rtlch \ltrch\loch\fs22
; total subject }{\i\afs22\ai\rtlch \ltrch\loch\fs22
n}{\afs22\rtlch \ltrch\loch\fs22
=1,406). Subjects contributed only whole periods }{\afs22\rtlch \ltrch\loch\fs22
(}{\afs22\rtlch \ltrch\loch\fs22
not }{\afs22\rtlch \ltrch\loch\fs22
contribut}{\afs22\rtlch \ltrch\loch\fs22
ing}{\afs22\rtlch \ltrch\loch\fs22
 to a period if it began before their first diagnosis of schizophrenia, or ended after their death}{\afs22\rtlch \ltrch\loch\fs22
)}{\afs22\rtlch \ltrch\loch\fs22
. }{{\*\bkmkend __DdeLink__9900_446909264}{\*\bkmkend __DdeLink__2057_2003706413}\afs22\rtlch \ltrch\loch\fs22
Analyses were fit using the R}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
18}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
 function lme}{\afs22\rtlch \ltrch\loch\fs22
rTest}{\afs22\rtlch \ltrch\loch\fs22
::lmer, }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
and }{\i\b0\afs22\ai\ab0\rtlch \ltrch\loch\fs22
p}{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
 values and 95%}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
confidence intervals (CIs) were calculated using the Satterthwaite degrees-of-freedom approximation }{\afs22\rtlch \ltrch\loch\fs22
and Type III sums of squares (estimating the effect of each predictor over and above the effect of all others, }{\afs22\rtlch \ltrch\loch\fs22
particularly relevant where predictors are correlated}{\afs22\rtlch \ltrch\loch\fs22
)}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{{\*\bkmkstart __DdeLink__560_1557498281}{\*\bkmkend __DdeLink__1558_10158622931}{\*\bkmkend __DdeLink__560_1557498281}\afs22\rtlch \ltrch\loch\fs22
Sulpiride, amisulpride, and mirtazapine are among drugs used for augmentation of treatment with clozapine}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
19}{\afs22\rtlch \ltrch\loch\fs22
, and co-prescription was common. We therefore added drug\u8211\'96drug interaction terms between clozapine and each of: sulpiride, amisulpride, mirtazapine, aripiprazole, and olanzapine (thereby including also interactions with other drugs associated with a reduction in admission-days in the 2-year mirror analysis). Since the }{{\*\bkmkstart __DdeLink__113_327567811}\afs22\rtlch \ltrch\loch\fs22
clozapine\u215\'d7}{{\*\bkmkend __DdeLink__113_327567811}\afs22\rtlch \ltrch\loch\fs22
sulpiride and clozapine\u215\'d7mirtazapine interactions were far from significant (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
p}{\afs22\rtlch \ltrch\loch\fs22
 > 0.5), our final regression model included interactions between clozapine and each of amisulpride, aripiprazole, and olanzapine, plus all main effects. To exclude the possibility that the effects attributed to non-clozapine drugs were due to a confound with clozapine treatment or vice versa, we re-ran the regression for the subset of patients who had received clozapine at some point, or only those who had not received clozapine.}
\par \pard\plain \s1\ilvl0\outlinelevel0\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb227\sa113\keepn\caps\b\dbch\af9\dbch\af10\afs28\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\b\afs22\rtlch \ltrch\loch\fs22
RESULTS}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\rtlch \ltrch\loch\fs22
Demographics}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj\sb0\sa119{\afs22\rtlch \ltrch\loch\fs22
1,485 patients }{\afs22\rtlch \ltrch\loch\fs22
had coded diagnoses of }{\afs22\rtlch \ltrch\loch\fs22
schizophrenia (}{\afs22\rtlch \ltrch\loch\fs22
941 male, 544 female; }{\afs22\rtlch \ltrch\loch\fs22
sex difference, \u967\'3f}{\super\afs22\rtlch \ltrch\loch\fs22
2}{{\*\bkmkend __DdeLink__501_618207270}\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 = 106, }{\i\afs22\ai\rtlch \ltrch\loch\fs22
p}{\afs22\rtlch \ltrch\loch\fs22
 = 6.89 }{\cf17\dbch\af8\afs22\rtlch \ltrch\loch\fs22\loch\f8
\u215\'d7 }{\afs22\rtlch \ltrch\loch\fs22
10}{\super\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{{\*\bkmkend __DdeLink__487_618207270}\super\afs22\rtlch \ltrch\loch\fs22
25}{{\*\bkmkend __DdeLink__1009_1529088695}\afs22\rtlch \ltrch\loch\fs22
). }{\afs22\rtlch \ltrch\loch\fs22
At the }{\afs22\rtlch \ltrch\loch\fs22
first electronically recorded diagnosis, t}{\afs22\rtlch \ltrch\loch\fs22
he }{\afs22\rtlch \ltrch\loch\fs22
median age was 38 (}{\afs22\rtlch \ltrch\loch\fs22
range }{\afs22\rtlch \ltrch\loch\fs22
13}{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
93, }{\afs22\rtlch \ltrch\loch\fs22
interquartile range 24 years, }{\afs22\rtlch \ltrch\loch\fs22
central }{\afs22\rtlch \ltrch\loch\fs22
95% of patients in the range }{\afs22\rtlch \ltrch\loch\fs22
18.0}{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
77.3}{\afs22\rtlch \ltrch\loch\fs22
), }{\afs22\rtlch \ltrch\loch\fs22
likely reflecting a relatively high proportion of patients with chronic schizophrenia}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
The data did not permit the accurate differentiation of new-onset schizophrenia versus chronic schizophrenia recorded electronically for the first time. }{\afs22\rtlch \ltrch\loch\fs22
The median period of follow-up was 4.98 years (from the first to the last letter/admission within the time range, calculable for 1,310 patients). }{\afs22\rtlch \ltrch\loch\fs22
The sampling method was designed to be specific rather than sensitive, and excludes any patients with schizophrenia whose diagnosis was recorded without ICD-10 coding, or for whom ICD-10 diagnoses were recorded }{\afs22\rtlch \ltrch\loch\fs22
only }{\afs22\rtlch \ltrch\loch\fs22
in free-text documents. }{\afs22\rtlch \ltrch\loch\fs22
Overall admission rates for schizophrenia declined }{\afs22\rtlch \ltrch\loch\fs22
substantially }{\afs22\rtlch \ltrch\loch\fs22
over time (}{\afs22\rtlch \ltrch\loch\fs22
from a mean of 49.3 days/year/patient in 2005 to 10.2 in 2012}{\afs22\rtlch \ltrch\loch\fs22
).}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\rtlch \ltrch\loch\fs22
Drug usage }{\i\afs22\rtlch \ltrch\loch\fs22
and sex differences in prescribing}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\i0\b\afs22\ai0\ab\rtlch \ltrch\loch\fs22
Table 1 }{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
shows }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
drug use }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
rates }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
for antipsychotics and antidepressants}{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
. }{\afs22\rtlch \ltrch\loch\fs22
Clozapine, olanzapine, and depot risperidone were all prescribed }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
proportionally }{\afs22\rtlch \ltrch\loch\fs22
more in males, }{\afs22\rtlch \ltrch\loch\fs22
with }{\afs22\rtlch \ltrch\loch\fs22
no other }{\afs22\rtlch \ltrch\loch\fs22
significant }{\afs22\rtlch \ltrch\loch\fs22
sex differences }{\afs22\rtlch \ltrch\loch\fs22
for }{\afs22\rtlch \ltrch\loch\fs22
antipsychotic}{\afs22\rtlch \ltrch\loch\fs22
s}{\afs22\rtlch \ltrch\loch\fs22
. 30.1% }{\afs22\rtlch \ltrch\loch\fs22
of males were }{\afs22\rtlch \ltrch\loch\fs22
prescribed clozapine at some point, }{\afs22\rtlch \ltrch\loch\fs22
and 21.9% of }{\afs22\rtlch \ltrch\loch\fs22
female}{\afs22\rtlch \ltrch\loch\fs22
s}{\afs22\rtlch \ltrch\loch\fs22
 (\u967\'3f}{\super\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
 test, }{\i\afs22\ai\rtlch \ltrch\loch\fs22
p}{\afs22\rtlch \ltrch\loch\fs22
 = 2.01 }{\cf17\dbch\af8\afs22\rtlch \ltrch\loch\fs22\loch\f8
\u215\'d7}{\afs22\rtlch \ltrch\loch\fs22
 10}{\super\afs22\rtlch \ltrch\loch\fs22
\u8211\'966}{\afs22\rtlch \ltrch\loch\fs22
). For olanzapine, these values were 42.1% and 34.4% (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
p}{\afs22\rtlch \ltrch\loch\fs22
 = 1.31 }{\cf17\dbch\af8\afs22\rtlch \ltrch\loch\fs22\loch\f8
\u215\'d7}{\afs22\rtlch \ltrch\loch\fs22
 10}{\super\afs22\rtlch \ltrch\loch\fs22
\u8211\'969}{\afs22\rtlch \ltrch\loch\fs22
); }{\afs22\rtlch \ltrch\loch\fs22
f}{\afs22\rtlch \ltrch\loch\fs22
or depot risperidone, 8.0% and 4.2% (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
p}{\afs22\rtlch \ltrch\loch\fs22
 = 0.0071). Females were more likely to be prescribed amitr}{\afs22\rtlch \ltrch\loch\fs22
i}{\afs22\rtlch \ltrch\loch\fs22
ptyline (5.9% versus 2.2%, uncorrected }{\i\afs22\ai\rtlch \ltrch\loch\fs22
p}{\afs22\rtlch \ltrch\loch\fs22
 = 4.5 }{\cf17\dbch\af8\afs22\rtlch \ltrch\loch\fs22\loch\f8
\u215\'d7}{\afs22\rtlch \ltrch\loch\fs22
 10}{\super\afs22\rtlch \ltrch\loch\fs22
\u8211\'964}{\afs22\rtlch \ltrch\loch\fs22
), and citalopram (18.0% versus 13.6%, }{\i\afs22\ai\rtlch \ltrch\loch\fs22
p}{\afs22\rtlch \ltrch\loch\fs22
 = }{\afs22\rtlch \ltrch\loch\fs22
0}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
0}{\afs22\rtlch \ltrch\loch\fs22
274), with no other }{\afs22\rtlch \ltrch\loch\fs22
significant }{\afs22\rtlch \ltrch\loch\fs22
sex differences for antidepressants.}{{\*\bkmkend __DdeLink__1491_1015862293}{\*\bkmkend __DdeLink__1484_1015862293}{\*\bkmkend __DdeLink__1486_1015862293}{\*\bkmkend __DdeLink__499_618207270}{\*\bkmkend __DdeLink__1482_1015862293}{\*\bkmkend __DdeLink__489_618207270}{\*\bkmkend __DdeLink__2324_273168210}\afs22\rtlch \ltrch\loch\fs22
 }{\b\afs22\ab\rtlch \ltrch\loch\fs22
Supplementary }{\b\afs22\ab\rtlch \ltrch\loch\fs22
Table }{\b\afs22\ab\rtlch \ltrch\loch\fs22
1}{\b\afs22\ab\rtlch \ltrch\loch\fs22
 }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
indicates frequency of consecutive or temporally close co-prescription between pairs of drugs, }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
and of monotherapy, }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
and shows all drugs included in the regression analysis.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\ai\rtlch \ltrch\loch\fs22
Precision and recall for clozapine}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj{\afs22\rtlch \ltrch\loch\fs22
For clozapine, recall was 1.0. Patient precision was 0.96. Temporal precision was 0.85.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\rtlch \ltrch\loch\fs22
Mirror analysis: relationship between drug use and admission}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj{\b\afs22\ab\rtlch \ltrch\loch\fs22
Figure }{\b\afs22\ab\rtlch \ltrch\loch\fs22
2}{\b\afs22\ab\rtlch \ltrch\loch\fs22
 }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
shows the m}{\afs22\rtlch \ltrch\loch\fs22
irror-image analyses}{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
.}{\b\afs22\ab\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
Drugs associated with fewer subsequent admissions in the 1-year analysis were amisulpride, aripiprazole, clozapine, fluoxetine, mirtazapine, olanzapine, quetiapine, and sulpiride. Drugs that continued to be associated with fewer subsequent admissions in the }{\afs22\rtlch \ltrch\loch\fs22
more stringent }{\afs22\rtlch \ltrch\loch\fs22
2-year analysis, despite fewer observations, were aripiprazole, clozapine, olanzapine, and sulpiride. In both analyses, sulpiride was associated with the largest reduction in subsequent admissions.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i\afs22\ai\rtlch \ltrch\loch\fs22
Regression analysis}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
In the regression analysis }{\b\afs22\ab\rtlch \ltrch\loch\fs22
(}{\b\afs22\ab\rtlch \ltrch\loch\fs22
Figure }{\b\afs22\ab\rtlch \ltrch\loch\fs22
3}{\b\afs22\ab\rtlch \ltrch\loch\fs22
)}{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
,}{\b\afs22\ab\rtlch \ltrch\loch\fs22
 }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
s}{\afs22\rtlch \ltrch\loch\fs22
ulpiride and mirtazapine continued to be associated with a reduction in admissions (estimated mean change \u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
20.4}{\afs22\rtlch \ltrch\loch\fs22
 and \u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
11.}{\afs22\rtlch \ltrch\loch\fs22
6}{\afs22\rtlch \ltrch\loch\fs22
 days/year, respectively). The changes were smaller than in the mirror analysis }{\afs22\rtlch \ltrch\loch\fs22
(expected }{\afs22\rtlch \ltrch\loch\fs22
since}{\afs22\rtlch \ltrch\loch\fs22
 all patients were included and statistical control for other factors was better)}{\afs22\rtlch \ltrch\loch\fs22
. Clozapine\u8211\'96aripiprazole and clozapine\u8211\'96amisulpride combinations were also associated with a significant decrease in admission rates, beyond the effect of either alone (interaction effects \u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
7}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
7}{\afs22\rtlch \ltrch\loch\fs22
 and \u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
3}{\afs22\rtlch \ltrch\loch\fs22
.8}{\afs22\rtlch \ltrch\loch\fs22
 days/year respectively), }{\afs22\rtlch \ltrch\loch\fs22
as was venlafaxine (\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
3}{\afs22\rtlch \ltrch\loch\fs22
)}{\afs22\rtlch \ltrch\loch\fs22
. As noted above, clozapine\u215\'d7sulpiride and clozapine\u215\'d7mirtazapine interactions were far from sign}{\afs22\rtlch \ltrch\loch\fs22
ificant in preliminary analysis. Some antipsychotics were associated with an increase in admission rates, although this method of analysis may be biased against drug effectiveness (see Discussion). }{\afs22\rtlch \ltrch\loch\fs22
T}{\afs22\rtlch \ltrch\loch\fs22
he }{\afs22\rtlch \ltrch\loch\fs22
overall }{\afs22\rtlch \ltrch\loch\fs22
mean }{\afs22\rtlch \ltrch\loch\fs22
admission rate was }{\afs22\rtlch \ltrch\loch\fs22
26.8 }{\afs22\rtlch \ltrch\loch\fs22
days/year}{\afs22\rtlch \ltrch\loch\fs22
. Admission rates decreased with time, but, in addition, }{\afs22\rtlch \ltrch\loch\fs22
time since diagnosis}{\afs22\rtlch \ltrch\loch\fs22
 was negatively associated with admissions}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj{{\*\bkmkstart __DdeLink__87_1858645441}\afs22\rtlch \ltrch\loch\fs22
Within patients who had received clozapine at some point (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
n}{\afs22\rtlch \ltrch\loch\fs22
=402)}{{\*\bkmkend __DdeLink__87_1858645441}\afs22\rtlch \ltrch\loch\fs22
, }{{\*\bkmkstart __DdeLink__89_1858645441}\afs22\rtlch \ltrch\loch\fs22
m}{{\*\bkmkend __DdeLink__89_1858645441}\afs22\rtlch \ltrch\loch\fs22
irtazapine continued to be negatively associated with admission days (mean change \u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
0}{\afs22\rtlch \ltrch\loch\fs22
 days/year}{{\*\bkmkstart __DdeLink__88_1557498281}\afs22\rtlch \ltrch\loch\fs22
, }{\afs22\rtlch \ltrch\loch\fs22
CI \u8211\'964}{\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
 to \u8211\'961.}{\afs22\rtlch \ltrch\loch\fs22
8}{{\*\bkmkend __DdeLink__88_1557498281}\afs22\rtlch \ltrch\loch\fs22
), while the effect}{\afs22\rtlch \ltrch\loch\fs22
s}{\afs22\rtlch \ltrch\loch\fs22
 of sulpiride }{\afs22\rtlch \ltrch\loch\fs22
or venlafaxine}{\afs22\rtlch \ltrch\loch\fs22
, while still negative, }{\afs22\rtlch \ltrch\loch\fs22
were}{\afs22\rtlch \ltrch\loch\fs22
 not credibly different from zero in this subgroup }{{\*\bkmkstart __DdeLink__90_1557498281}\afs22\rtlch \ltrch\loch\fs22
(}{\afs22\rtlch \ltrch\loch\fs22
sulpiride }{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
18.}{\afs22\rtlch \ltrch\loch\fs22
8}{\afs22\rtlch \ltrch\loch\fs22
, CI \u8211\'9637.}{\afs22\rtlch \ltrch\loch\fs22
7}{\afs22\rtlch \ltrch\loch\fs22
 to +0.}{\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
; }{\afs22\rtlch \ltrch\loch\fs22
venlafaxine, }{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
.4, CI }{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
3}{\afs22\rtlch \ltrch\loch\fs22
5}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
5}{\afs22\rtlch \ltrch\loch\fs22
 to +1}{\afs22\rtlch \ltrch\loch\fs22
0}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
7}{\afs22\rtlch \ltrch\loch\fs22
)}{{\*\bkmkend __DdeLink__90_1557498281}\afs22\rtlch \ltrch\loch\fs22
. Within the group of patients who had not received clozapine (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
n}{\afs22\rtlch \ltrch\loch\fs22
=1,083), }{{\*\bkmkstart __DdeLink__91_1858645441}\afs22\rtlch \ltrch\loch\fs22
t}{{\*\bkmkend __DdeLink__91_1858645441}\afs22\rtlch \ltrch\loch\fs22
he effect of sulpiride remained strong (mean \u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
9}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
9}{\afs22\rtlch \ltrch\loch\fs22
, CI \u8211\'963}{\afs22\rtlch \ltrch\loch\fs22
6}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
0}{\afs22\rtlch \ltrch\loch\fs22
 to \u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
3}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
8}{\afs22\rtlch \ltrch\loch\fs22
), while the effect}{\afs22\rtlch \ltrch\loch\fs22
s}{\afs22\rtlch \ltrch\loch\fs22
 of mirtazapine }{\afs22\rtlch \ltrch\loch\fs22
and venlafaxine }{{\*\bkmkstart __DdeLink__101_1858645441}\afs22\rtlch \ltrch\loch\fs22
were}{\afs22\rtlch \ltrch\loch\fs22
 not }{{\*\bkmkend __DdeLink__101_1858645441}\afs22\rtlch \ltrch\loch\fs22
credibly different from zero (}{\afs22\rtlch \ltrch\loch\fs22
mirtazapine }{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
4.}{\afs22\rtlch \ltrch\loch\fs22
7}{\afs22\rtlch \ltrch\loch\fs22
, CI \u8211\'9613.}{\afs22\rtlch \ltrch\loch\fs22
5}{\afs22\rtlch \ltrch\loch\fs22
 to +}{\afs22\rtlch \ltrch\loch\fs22
4}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
, }{\afs22\rtlch \ltrch\loch\fs22
venlafaxine }{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
8.}{\afs22\rtlch \ltrch\loch\fs22
7}{\afs22\rtlch \ltrch\loch\fs22
, CI }{\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{\afs22\rtlch \ltrch\loch\fs22
20.6}{\afs22\rtlch \ltrch\loch\fs22
 to +3.}{\afs22\rtlch \ltrch\loch\fs22
3}{\afs22\rtlch \ltrch\loch\fs22
).}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj{\afs22\rtlch \ltrch\loch\fs22
Thus, the effect of mirtazapine was statistically independent of that of clozapine, though numerically stronger in clozapine users; clozapine and aripiprazole showed significant beneficial synergistic effects, as did clozapine and amisulpride; and sulpiride showed the largest beneficial effect overall, which was not solely due to its use as an augmentation strategy for clozapine.}
\par \pard\plain \s1\ilvl0\outlinelevel0\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb227\sa113\keepn\caps\b\dbch\af9\dbch\af10\afs28\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\cf1\b\rtlch \ltrch\loch
DISCUSSION}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\afs22\rtlch \ltrch\loch\fs22
In patients with schizophrenia, we found a significant decrease in }{\afs22\rtlch \ltrch\loch\fs22
admission-days }{\afs22\rtlch \ltrch\loch\fs22
after initiation of sulpiride, aripiprazole, clozapine, and olanzapine, in mirror-image analyses covering 2 years before and after drug initiation. This analysis focused on patients with more severe disease, in that they had at least one hospital admission in the pre-drug period. Sulpiride, mirtazapine, }{\afs22\rtlch \ltrch\loch\fs22
venlafaxine, }{\afs22\rtlch \ltrch\loch\fs22
and clozapine}{{\*\bkmkstart __DdeLink__117_327567811}{\*\bkmkstart __DdeLink__115_327567811}\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{{\*\bkmkend __DdeLink__117_327567811}{\*\bkmkend __DdeLink__115_327567811}\afs22\rtlch \ltrch\loch\fs22
aripiprazole and clozapine\u8211\'96amisulpride combinations were associated with a decrease in subsequent time spent in hospital in a regression analysis across all 1,406 patients, controlling for the effects of other drugs. All analyses controlled for overall changes in admission rates unrelated to drug use. Some drugs in the regression analysis were associated with an increase in admissions; however, this method may be biased against drug efficacy }{\afs22\rtlch \ltrch\loch\fs22
(discussed below)}{\afs22\rtlch \ltrch\loch\fs22
, so we do not rely on changes in this direction. In all analyses, the largest beneficial effects were associated with sulpiride, a drug used relatively infrequently in local practice.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\rtlch \ltrch\loch
Methodological considerations}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
I}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
n the mirror-image design, we studied patients who were relatively unwell by }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
considering only }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
patients who had been admitted in the pre-drug period. }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
Additional strengths }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
of this analysis }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
are}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
 that it }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
examines a relatively long time period, }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
represents a within-subjects comparison, and }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
is }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
an intention-to-treat analysis, since subjects who commenced and then stopped a given drug are not distinguished from those who started and continued \u8211\'96 in this respect unlike}{{\*\bkmkend _ENREF_13}\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\ai0\rtlch \ltrch\loch\fs22
17}{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
. }{\afs22\rtlch \ltrch\loch\fs22
A weakness of this method is the potential for influence by regression to the mean. If illness course fluctuates spontaneously and drugs are started when the illness is severe, natural variation will bias the results in favour of drug treatments. We attempted to reduce this by the use of the central }{\afs22\rtlch \ltrch\loch\fs22
exclusion }{\afs22\rtlch \ltrch\loch\fs22
gap but also by using both a temporally narrow mirror-image analysis (M = 1 year) and a temporally broad analysis (M = 2 years). Any effect of regression to the mean is less likely to be observed in the temporally broader analysis. }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
An additional weakness of the mirror-image design is that it takes no account of other drugs given at the same time; }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
we addressed this }{\i0\afs22\ai0\rtlch \ltrch\loch\fs22
with a regression analysis.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa119{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
The regression analysis accounted for the effects of all drugs considered simultaneously }{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
(examining the effects of each drug over and above all others)}{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
, accounted for }{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
age and }{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
estimated illness duration (over and above calendar }{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
time}{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
), and examined drug\u8211\'96drug interactions. A weakness of this method is that }{\i\b0\afs22\ai\ab0\rtlch \ltrch\loch\fs22
a priori}{\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22
 one might expect admissions to be associated with more frequent documentation in secondary care of a drug history. This would bias the analysis against effective drugs; therefore, we do not rely on effects in that direction. However, the analysis highlights drugs associated with the greatest decrease in admission days. Another weakness is that admissions may trigger the initiation of treatment (so causality might flow from admissions to drugs rather than the reverse).}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\rtlch \ltrch\loch
Comparison to other studies of efficacy and hospitalization in schizophrenia}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\afs22\rtlch \ltrch\loch\fs22
Our results are broadly in line with previous evidence of antipsychotic efficacy as judged by changes in symptoms or hospitalization. A recent meta-analysis}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
20}{\afs22\rtlch \ltrch\loch\fs22
 ranked clozapine, amisulpride, and olanzapine as the top three for improving symptoms of schizophrenia and for lack of all-cause discontinuation, a combination that might be expected to reduce hospitalization. Hospitalization benefits for clozapine and olanzapine have also been observed before. }{\afs22\rtlch \ltrch\loch\fs22
A double-blind r}{\afs22\rtlch \ltrch\loch\fs22
andomized trial }{\afs22\rtlch \ltrch\loch\fs22
favour}{\afs22\rtlch \ltrch\loch\fs22
ed}{\afs22\rtlch \ltrch\loch\fs22
 olanzapine over perphenazine, quetiapine, risperidone, or ziprasidone }{\afs22\rtlch \ltrch\loch\fs22
for re-hospitalization}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
, }{\afs22\rtlch \ltrch\loch\fs22
and a non-blind randomized trial favoured clozapine over usual care}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
3}{\afs22\rtlch \ltrch\loch\fs22
.}{\afs22\rtlch \ltrch\loch\fs22
 }{\afs22\rtlch \ltrch\loch\fs22
Non-randomized studies have found hospitalization advantages for clozapine, versus risperidone or SGAs collectively}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
4}{\afs22\rtlch \ltrch\loch\fs22
, }{\afs22\rtlch \ltrch\loch\fs22
FGAs}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
5}{\afs22\rtlch \ltrch\loch\fs22
, }{\afs22\rtlch \ltrch\loch\fs22
depot FGAs}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
6}{\afs22\rtlch \ltrch\loch\fs22
, or }{\afs22\rtlch \ltrch\loch\fs22
a pre-clozapine period}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
7}{\afs22\rtlch \ltrch\loch\fs22
. After a first hospitalization for schizophrenia/schizoaffective disorder, the lowest risk of rehospitalization was associated with the use of olanzapine, clozapine, and perphenazine depot}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
8}{\afs22\rtlch \ltrch\loch\fs22
. Th}{\afs22\rtlch \ltrch\loch\fs22
at}{\afs22\rtlch \ltrch\loch\fs22
 study did not examine some drugs associated with fewer admission-days in our analysis (sulpiride, aripiprazole, mirtazapine) and perphenazine was not used sufficiently in our sample for analysis, but olanzapine and clozapine were associated with positive benefit in terms of hospitalization in both studies (at least, in our study, for patients having more frequent admissions within the mirror-image analysis).}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0{\afs22\rtlch \ltrch\loch\fs22
A}{\afs22\rtlch \ltrch\loch\fs22
ripiprazole and amisulpride were associated with benefit when combined with clozapine. Aripiprazole monotherapy has not shown better efficacy than other antipsychotics on reducing re-admission}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
21}{\afs22\rtlch \ltrch\loch\fs22
; however, its use for clozapine augmentation has shown benefit}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
9,10}{\afs22\rtlch \ltrch\loch\fs22
. Two small studies have shown some benefits for amisulpride as clozapine augmentation}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
22,23}{\afs22\rtlch \ltrch\loch\fs22
. }{\afs22\rtlch \ltrch\loch\fs22
Overall, 27.1% of patients }{\afs22\rtlch \ltrch\loch\fs22
in our study had been }{\afs22\rtlch \ltrch\loch\fs22
prescribed clozapine at some point, }{\afs22\rtlch \ltrch\loch\fs22
within the expected range}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
24,25}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0{\afs22\rtlch \ltrch\loch\fs22
Mirtazapine was associated with }{\afs22\rtlch \ltrch\loch\fs22
fewer}{\afs22\rtlch \ltrch\loch\fs22
 admission-}{\afs22\rtlch \ltrch\loch\fs22
days}{\afs22\rtlch \ltrch\loch\fs22
, in analyses controll}{\afs22\rtlch \ltrch\loch\fs22
ing}{\afs22\rtlch \ltrch\loch\fs22
 for other drugs. This was statistically independent of clozapine. No studies have specifically examined the impact of mirtazapine }{\afs22\rtlch \ltrch\loch\fs22
or venlafaxine}{\afs22\rtlch \ltrch\loch\fs22
 on admission}{\afs22\rtlch \ltrch\loch\fs22
s}{\afs22\rtlch \ltrch\loch\fs22
 in schizophrenia; however, there is increasing (though heterogeneous) evidence that }{\afs22\rtlch \ltrch\loch\fs22
adding }{\afs22\rtlch \ltrch\loch\fs22
mirtazapine can improve negative/cognitive symptoms}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
11}{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
. }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
Treatment of depression in schizophrenia might also be an important mode of action, though the effects of four other conventional antidepressants, flupentixol, }{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
or}{\b0\afs22\ab0\rtlch \ltrch\loch\fs22
 quetiapine upon admissions were not significant or not beneficial}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0{\afs22\rtlch \ltrch\loch\fs22
Perhaps the most striking result in our study was the consistent and large reduction in admissions associated with sulpiride. The CUtLASS 1 study}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
26}{\afs22\rtlch \ltrch\loch\fs22
 found that SGAs were not superior to FGAs, favouring FGAs; of those FGAs, sulpiride was a common choice. A previous systematic review found little difference between sulpiride and other antipsychotics}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
27}{\afs22\rtlch \ltrch\loch\fs22
. However, a recent large epidemiological study found sulpiride to be associated with less discontinuation than haloperidol, risperidone, or olanzapine, and similarly less hospitalization, though the latter difference was not significant}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
28}{\afs22\rtlch \ltrch\loch\fs22
. There is also some evidence for the use of sulpiride as clozapine augmentation}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
29}{\afs22\rtlch \ltrch\loch\fs22
, }{\afs22\rtlch \ltrch\loch\fs22
though in our data the sulpiride effect did not interact with that of clozapine}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\rtlch \ltrch\loch
Study }{\rtlch \ltrch\loch
strengths}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa113{\afs22\rtlch \ltrch\loch\fs22
This study has strengths as }{\afs22\rtlch \ltrch\loch\fs22
a naturalistic observational study across a healthcare provider, covering a wide range of patient ages and clinical teams, with natural variation in prescribing practice. }{\afs22\rtlch \ltrch\loch\fs22
The analytical methods }{\afs22\rtlch \ltrch\loch\fs22
examine}{\afs22\rtlch \ltrch\loch\fs22
d}{\afs22\rtlch \ltrch\loch\fs22
 the within-subject effects of }{\afs22\rtlch \ltrch\loch\fs22
all antipsychotics and antidepressants}{\afs22\rtlch \ltrch\loch\fs22
 in common use, controlling statistically for }{\afs22\rtlch \ltrch\loch\fs22
the effects of the other drugs in use }{\afs22\rtlch \ltrch\loch\fs22
and for temporal factors.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa113{\i\afs22\ai\rtlch \ltrch\loch\fs22
Study weaknesses}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa113{\afs22\rtlch \ltrch\loch\fs22
Amongst its }{\afs22\rtlch \ltrch\loch\fs22
several }{\afs22\rtlch \ltrch\loch\fs22
weaknesses, t}{\afs22\rtlch \ltrch\loch\fs22
he study is observational, not interventional, so causal conclusions cannot be drawn. For example, a particular drug associated with better outcomes may itself be used preferentially by clinical teams that deliver better care, or be prescribed more for patients }{\afs22\rtlch \ltrch\loch\fs22
whose disease is more responsive to treatment}{\afs22\rtlch \ltrch\loch\fs22
, or some other such unmeasured confound. Conversely, a drug may be }{\afs22\rtlch \ltrch\loch\fs22
spuriously }{\afs22\rtlch \ltrch\loch\fs22
associated with worse outcomes because it is perceived to be clinically effective and is therefore prescribed for more severely ill patients at the start of a psychiatric admission. }
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa113{\afs22\rtlch \ltrch\loch\fs22
Some drugs were recorded at median doses below the therapeutic minimum (}{\b\afs22\ab\rtlch \ltrch\loch\fs22
Table 1}{\afs22\rtlch \ltrch\loch\fs22
), specifically chlorpromazine, pipotiazine, and clozapine. This represents a source of bias against these drugs\u8217\'92 effectiveness. }{\afs22\rtlch \ltrch\loch\fs22
In some cases the doses were systematically underestimated by the NLP-generated drug histories, notably for split-dose drugs such as clozapine}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s0\nowidctlpar\hyphpar0\aspalpha\ltrpar\cf0\kerning1\dbch\af9\langfe2052\dbch\af10\afs24\alang1081\loch\f3\fs24\lang2057{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0{\afs22\rtlch \ltrch\loch\fs22
Additionally, the data are noisy and/or incomplete for several reasons, }{\afs22\rtlch \ltrch\loch\fs22
leading to a reduction in power and potential bias}{\afs22\rtlch \ltrch\loch\fs22
. There is  likely to have been under-recording of schizophrenia diagnoses, given the generally low rates of ICD-10 diagnostic coding. In this respect we preferred specificity over sensitivity, but it is possible that there was a systematic difference between patients with schizophrenia who did and did not have their diagnosis electronically coded. }{\afs22\rtlch \ltrch\loch\fs22
The temporal precision of NLP-generated drug histories was imperfect. }{\afs22\rtlch \ltrch\loch\fs22
Concomitant treatments (such as psychotherapy or electroconvulsive therapy) and concomitant physical illnesses were not measured and represent an additional source of noise and potential bias. }{\afs22\rtlch \ltrch\loch\fs22
Since the drug data are based on NLP analysis of clinical documents representing snapshots of each patient when seen in secondary care, use of a given drug between snapshots was not measured. }{\afs22\rtlch \ltrch\loch\fs22
This weakness prohibits also accurate characterization of the duration of use of individual drugs, necessitating an intention-to-treat approach and likely lowering power (since drugs used only briefly are thus included), and did not permit an accurate characterization of illness course.}{\afs22\rtlch \ltrch\loch\fs22
 Our data are of }{\afs22\rtlch \ltrch\loch\fs22
significantly }{\afs22\rtlch \ltrch\loch\fs22
lower quality than large data sets including electronic prescription and dispensing information}{\scaps0\caps0\super\i0\ulnone\ulc0\b0\afs22\rtlch \ltrch\loch\fs22
30,31}{\afs22\rtlch \ltrch\loch\fs22
; however, they may nonetheless provide novel suggestions.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa113{\afs22\rtlch \ltrch\loch\fs22
The overall decline in admissions }{\afs22\rtlch \ltrch\loch\fs22
is likely to represent primarily service reorganizations leading to a shift in admission threshold, thought might also }{\afs22\rtlch \ltrch\loch\fs22
reflect}{\afs22\rtlch \ltrch\loch\fs22
 a degree of artefact of loss to follow-up of patients moving to other geographical areas, or improvements in treatment}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s2\ilvl1\outlinelevel1\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb113\sa113\keepn\i\b0\dbch\af9\dbch\af10\afs32\ab\loch\f5\fs22{\listtext\pard\plain \tab}\ls1 \li576\ri0\lin576\rin0\fi-576\sl480\slmult1\li0\ri0\lin0\rin0\fi0{\rtlch \ltrch\loch
Conclusions}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa113{\afs22\rtlch \ltrch\loch\fs22
In an observational study of 1,485 patients with schizophrenia in a secondary mental health care setting, the initiation of sulpiride, mirtazapine, }{\afs22\rtlch \ltrch\loch\fs22
venlafaxine, }{\afs22\rtlch \ltrch\loch\fs22
or clozapine}{{\*\bkmkstart __DdeLink__121_540467755}\afs22\rtlch \ltrch\loch\fs22
\u8211\'96}{{\*\bkmkend __DdeLink__121_540467755}\afs22\rtlch \ltrch\loch\fs22
aripiprazole and clozapine\u8211\'96amisulpride combinations was associated with a decrease in subsequent time spent in hospital, controlling for other drugs. In simple comparisons of admissions before and after each drug was started, sulpiride, aripiprazole, clozapine, and olanzapine were associated with a reduction in subsequent admissions, for patients admitted in the pre-drug period. The association of clozapine and olanzapine with a reduction in subsequent admissions has been observed before, as have some benefits for amisulpride and aripiprazole as clozapine augmentation, but the association of sulpiride, mirtazapine, }{\afs22\rtlch \ltrch\loch\fs22
and venlafaxine}{\afs22\rtlch \ltrch\loch\fs22
 with these benefits is novel. Sulpiride was associated with the greatest reduction in inpatient days in all analyses, independent}{\afs22\rtlch \ltrch\loch\fs22
ly}{\afs22\rtlch \ltrch\loch\fs22
 of clozapine use. These findings }{\afs22\rtlch \ltrch\loch\fs22
are not conclusive, }{\afs22\rtlch \ltrch\loch\fs22
do not imply causation,}{\afs22\rtlch \ltrch\loch\fs22
 and }{\afs22\rtlch \ltrch\loch\fs22
should not be used to alter clinical practice but raise hypotheses requiring}{\afs22\rtlch \ltrch\loch\fs22
 confirmation }{\afs22\rtlch \ltrch\loch\fs22
or refutation }{\afs22\rtlch \ltrch\loch\fs22
by randomized controlled trials.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\b\ab\rtlch \ltrch\loch

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
ACKNOWLEDGEMENTS}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\rtlch \ltrch\loch
We thank Rob Stewart, Matthew Broadbent, Ed Bullmore, and Jonathan Lewis for advice and support, }{\rtlch \ltrch\loch
and two anonymous referees for helpful comments.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
C}{\b\ab\rtlch \ltrch\loch
OMPETING INTERESTS}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\cf0\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22\lang1033
EF has received unrestricted research funding from Genus Pharmaceuticals, and consultancy fees from Roche/Genentech. The authors declare that they have no other }{\cf0\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22\lang1033
conflicts of interest in relation to the subject of this study}{\cf0\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22\lang1033
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
CONTRIBUTIONS}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b0\ab0\rtlch \ltrch\loch
RNC designed the analyses, }{\b0\ab0\rtlch \ltrch\loch
had access to all the data reported, takes responsibility for the integrity of the data and the accuracy of the data analysis, }{\b0\ab0\rtlch \ltrch\loch
analysed the data, }{\b0\ab0\rtlch \ltrch\loch
and }{\b0\ab0\rtlch \ltrch\loch
wrote the manuscript. GS }{\b0\ab0\rtlch \ltrch\loch
obtained institutional approvals, }{\b0\ab0\rtlch \ltrch\loch
analysed data and wrote the manuscript. LM wrote the manuscript. EF designed the study and wrote the manuscript.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
FUNDING}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b0\ab0\rtlch \ltrch\loch
RNC was supported by the Wellcome Trust. EFE was supported by a NARSAD Young Investigator Award. The CPFT Research Database was supported by the UK National Institute of Health Research Cambridge Biomedical Research Centre. The work was conducted within the Behavioural and Clinical Neuroscience Institute, supported by the Wellcome Trust and the UK }{\b0\ab0\rtlch \ltrch\loch
Medical Research Council.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b\ab\rtlch \ltrch\loch
S}{\b\ab\rtlch \ltrch\loch
UPPLEMENTARY MATERIAL}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1{\b0\ab0\rtlch \ltrch\loch
Supplementary information is available at }{\i\b0\ai\ab0\rtlch \ltrch\loch
npj Schizophrenia}{\i0\b0\ai0\ab0\rtlch \ltrch\loch
\u8217\'92s website.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\cf0\i0\b0\afs22\ai0\ab0\rtlch \ltrch\loch\fs22\lang1033

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22{\listtext\pard\plain \i0\b\highlight7\dbch\af7\afs22\ai0\ab\loch\f6\fs22}\ilvl0\ls2 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa113\b0\ab0\rtlch \ltrch\loch

\par \pard\plain \s1\ilvl0\outlinelevel0\sl360\slmult1\li0\ri0\lin0\rin0\fi0\sb227\sa113\keepn\caps\b\dbch\af9\dbch\af10\afs28\loch\f5\fs22\pagebb{\listtext\pard\plain \tab}\ls1 \li432\ri0\lin432\rin0\fi-432\sl480\slmult1\qj\li0\ri0\lin0\rin0\fi0\sb0\sa200{{\*\bkmkend _ENREF_6}\cf1\b\afs22\ab\rtlch \ltrch\loch\fs22
REFERENCES}
\par \sect\sectd\linemod5\linex283\linecont\sectunlocked1\pgwsxn11906\pghsxn16838\marglsxn1440\margrsxn1440\margtsxn1976\headery1440\margbsxn1440\ltrsect\sbknone\pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\rtlch \ltrch\loch
1 }{\rtlch \ltrch\loch
\tab NICE. CG178 Psychosis and schizophrenia in adults: treatment and management. 2014. (http://guidance.nice.org.uk/CG178).}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\rtlch \ltrch\loch
2 \tab Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, }{\i\rtlch \ltrch\loch
et al.}{\i0\rtlch \ltrch\loch
 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. }{\i\rtlch \ltrch\loch
N Engl J Med}{\i0\rtlch \ltrch\loch
 2005; }{\i0\b\rtlch \ltrch\loch
353}{\i0\b0\rtlch \ltrch\loch
: 1209\u8211\'9623.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
3 \tab Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine\u8217\'92s effectiveness for patients in state hospitals: results from a randomized trial. }{\i\b0\rtlch \ltrch\loch
Psychopharmacol Bull}{\i0\b0\rtlch \ltrch\loch
 1996; }{\i0\b\rtlch \ltrch\loch
32}{\i0\b0\rtlch \ltrch\loch
: 683\u8211\'9697.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
4 \tab Werneck AP, Hallak JC, Nakano E, Elkis H. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. }{\i\b0\rtlch \ltrch\loch
Psychiatry Res}{\i0\b0\rtlch \ltrch\loch
 2011; }{\i0\b\rtlch \ltrch\loch
188}{\i0\b0\rtlch \ltrch\loch
: 315\u8211\'969.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
5 \tab Pollack S, Woerner MG, Howard A, Fireworker RB, Kane JM. Clozapine reduces rehospitalization among schizophrenia patients. }{\i\b0\rtlch \ltrch\loch
Psychopharmacol Bull}{\i0\b0\rtlch \ltrch\loch
 1998; }{\i0\b\rtlch \ltrch\loch
34}{\i0\b0\rtlch \ltrch\loch
: 89\u8211\'9692.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
6 \tab Valevski A, Gilat Y, Olfson M, Benaroya-Milshtein N, Weizman A. Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: effect on time to readmission. }{\i\b0\rtlch \ltrch\loch
Int Clin Psychopharmacol}{\i0\b0\rtlch \ltrch\loch
 2012; }{\i0\b\rtlch \ltrch\loch
27}{\i0\b0\rtlch \ltrch\loch
: 159\u8211\'9664.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
7 \tab Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. }{\i\b0\rtlch \ltrch\loch
J Psychopharmacol Oxf Engl}{\i0\b0\rtlch \ltrch\loch
 2002; }{\i0\b\rtlch \ltrch\loch
16}{\i0\b0\rtlch \ltrch\loch
: 169\u8211\'9675.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
8 \tab Tiihonen J, Wahlbeck K, L\u246\'f6nnqvist J, Klaukka T, Ioannidis JPA, Volavka J, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. }{\i\b0\rtlch \ltrch\loch
BMJ}{\i0\b0\rtlch \ltrch\loch
 2006; }{\i0\b\rtlch \ltrch\loch
333}{\i0\b0\rtlch \ltrch\loch
: 224.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
9 \tab Cipriani A, Accordini S, Nos\u232\'e8 M, Purgato M, Girlanda F, Tansella M, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. }{\i\b0\rtlch \ltrch\loch
J Clin Psychopharmacol}{\i0\b0\rtlch \ltrch\loch
 2013; }{\i0\b\rtlch \ltrch\loch
33}{\i0\b0\rtlch \ltrch\loch
: 533\u8211\'967.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
10 \tab Muscatello MRA, Bruno A, Pandolfo G, Mic\u242\'f2 U, Scimeca G, Di Nardo F, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. }{\i\b0\rtlch \ltrch\loch
Schizophr Res}{\i0\b0\rtlch \ltrch\loch
 2011; }{\i0\b\rtlch \ltrch\loch
127}{\i0\b0\rtlch \ltrch\loch
: 93\u8211\'969.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
11 \tab Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S. Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia. }{\i\b0\rtlch \ltrch\loch
Clin Schizophr Relat Psychoses}{\i0\b0\rtlch \ltrch\loch
 2013; : 1\u8211\'9624.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
12 \tab Cambridgeshire County Council Research and Performance Team. Technical Report (April 2013): Population, Housing and Employment Forecasts. , 2013 (https://www.cambridge.gov.uk/sites/www.cambridge.gov.uk/files/documents/Population,%20Housing%20and%20Employment%20Forecasts%202013.pdf).}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
13 \tab Fernandes AC, Cloete D, Broadbent MTM, Hayes RD, Chang C-K, Jackson RG, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Development and evaluation of a de-identification procedure for a case register sourced from mental health electronic records. }{\i\b0\rtlch \ltrch\loch
BMC Med Inform Decis Mak}{\i0\b0\rtlch \ltrch\loch
 2013; }{\i0\b\rtlch \ltrch\loch
13}{\i0\b0\rtlch \ltrch\loch
: 71.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
14 \tab Cunningham H, Tablan V, Roberts A, Bontcheva K. Getting more out of biomedical documents with GATE\u8217\'92s full lifecycle open source text analytics. }{\i\b0\rtlch \ltrch\loch
PLoS Comput Biol}{\i0\b0\rtlch \ltrch\loch
 2013; }{\i0\b\rtlch \ltrch\loch
9}{\i0\b0\rtlch \ltrch\loch
: e1002854.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
15 \tab Sultana J, Chang CK, Hayes RD, Broadbent M, Stewart R, Corbett A, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study. }{\i\b0\rtlch \ltrch\loch
Int J Geriatr Psychiatry}{\i0\b0\rtlch \ltrch\loch
 2014. doi:10.1002/gps.4101.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
16 \tab World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines (CDDG). 1992. (http://www.who.int/entity/classifications/icd/en/bluebook.pdf).}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
17 \tab Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. }{\i\b0\rtlch \ltrch\loch
J Clin Psychopharmacol}{\i0\b0\rtlch \ltrch\loch
 2012; }{\i0\b\rtlch \ltrch\loch
32}{\i0\b0\rtlch \ltrch\loch
: 678\u8211\'9683.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
18 \tab R Core Team. }{\i\b0\rtlch \ltrch\loch
R: A language and environment for statistical computing}{\i0\b0\rtlch \ltrch\loch
. R Foundation for Statistical Computing, 2015 (http://www.R-project.org/).}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
19 \tab Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. }{\i\b0\rtlch \ltrch\loch
Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol}{\i0\b0\rtlch \ltrch\loch
 2012; }{\i0\b\rtlch \ltrch\loch
22}{\i0\b0\rtlch \ltrch\loch
: 165\u8211\'9682.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
20 \tab Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. }{\i\b0\rtlch \ltrch\loch
Lancet}{\i0\b0\rtlch \ltrch\loch
 2013; }{\i0\b\rtlch \ltrch\loch
382}{\i0\b0\rtlch \ltrch\loch
: 951\u8211\'9662.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
21 \tab Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. }{\i\b0\rtlch \ltrch\loch
J Clin Psychiatry}{\i0\b0\rtlch \ltrch\loch
 2006; }{\i0\b\rtlch \ltrch\loch
67}{\i0\b0\rtlch \ltrch\loch
: 1942\u8211\'967.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
22 \tab Assion H-J, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. }{\i\b0\rtlch \ltrch\loch
Pharmacopsychiatry}{\i0\b0\rtlch \ltrch\loch
 2008; }{\i0\b\rtlch \ltrch\loch
41}{\i0\b0\rtlch \ltrch\loch
: 24\u8211\'968.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
23 \tab Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. }{\i\b0\rtlch \ltrch\loch
Int Clin Psychopharmacol}{\i0\b0\rtlch \ltrch\loch
 2006; }{\i0\b\rtlch \ltrch\loch
21}{\i0\b0\rtlch \ltrch\loch
: 99\u8211\'96103.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
24 \tab Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. }{\i\b0\rtlch \ltrch\loch
Curr Med Res Opin}{\i0\b0\rtlch \ltrch\loch
 1997; }{\i0\b\rtlch \ltrch\loch
14}{\i0\b0\rtlch \ltrch\loch
: 1\u8211\'9620.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
25 \tab Royal College of Psychiatrists. Report of the second round of the National Audit of Schizophrenia (NAS) 2014. Healthcare Quality Improvement Partnership, 2014.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
26 \tab Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). }{\i\b0\rtlch \ltrch\loch
Arch Gen Psychiatry}{\i0\b0\rtlch \ltrch\loch
 2006; }{\i0\b\rtlch \ltrch\loch
63}{\i0\b0\rtlch \ltrch\loch
: 1079\u8211\'9687.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
27 \tab Omori IM, Wang J. Sulpiride versus placebo for schizophrenia. }{\i\b0\rtlch \ltrch\loch
Cochrane Database Syst Rev}{\i0\b0\rtlch \ltrch\loch
 2009; : CD007811.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
28 \tab Lai EC-C, Chang C-H, Kao Yang Y-H, Lin S-J, Lin C-Y. Effectiveness of sulpiride in adult patients with schizophrenia. }{\i\b0\rtlch \ltrch\loch
Schizophr Bull}{\i0\b0\rtlch \ltrch\loch
 2013; }{\i0\b\rtlch \ltrch\loch
39}{\i0\b0\rtlch \ltrch\loch
: 673\u8211\'9683.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
29 \tab Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. }{\i\b0\rtlch \ltrch\loch
Cochrane Database Syst Rev}{\i0\b0\rtlch \ltrch\loch
 2010; : CD008125.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
30 \tab Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, }{\i\b0\rtlch \ltrch\loch
et al.}{\i0\b0\rtlch \ltrch\loch
 Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. }{\i\b0\rtlch \ltrch\loch
Med Care}{\i0\b0\rtlch \ltrch\loch
 2002; }{\i0\b\rtlch \ltrch\loch
40}{\i0\b0\rtlch \ltrch\loch
: 630\u8211\'969.}
\par \pard\plain \s35\sl480\slmult1\tx768\li384\ri0\lin384\rin0\fi-384\sb0\sa240\noline\dbch\af11\loch\f5\fs22{\i0\b0\rtlch \ltrch\loch
31 \tab Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. }{\i\b0\rtlch \ltrch\loch
J Clin Psychiatry}{\i0\b0\rtlch \ltrch\loch
 2011; }{\i0\b\rtlch \ltrch\loch
72}{\i0\b0\rtlch \ltrch\loch
: 1079\u8211\'9685.}
\par \sect\sectd\linemod5\linex283\linecont\sectunlocked1\pgwsxn11906\pghsxn16838\marglsxn1440\margrsxn1440\margtsxn1976\headery1440\margbsxn1440\pgndec\sbknone\pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\rtlch \ltrch\loch

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\rtlch \ltrch\loch

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\rtlch \ltrch\loch

\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\pagebb\sl480\slmult1{\b\ab\rtlch \ltrch\loch
FIGURE LEGENDS}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj{\b\afs22\ab\rtlch \ltrch\loch\fs22
Figure 1.}{\afs22\rtlch \ltrch\loch\fs22
 Illustration of the mirror-image design. For a given drug, the number of admission-days for a given patient was calculated }{\afs22\rtlch \ltrch\loch\fs22
for}{\afs22\rtlch \ltrch\loch\fs22
 a period before }{\afs22\rtlch \ltrch\loch\fs22
the first recorded use of the drug }{\afs22\rtlch \ltrch\loch\fs22
(M}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
, either 1 or 2 years), and a period of identical duration afterwards (M}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
). }{\afs22\rtlch \ltrch\loch\fs22
These r}{\afs22\rtlch \ltrch\loch\fs22
ates were then corrected for the overall admission rates, for all patients with schizophrenia, during the same M}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 and M}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
 periods (see text). Patients were excluded who had no admissions falling in the M}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 period, }{\afs22\rtlch \ltrch\loch\fs22
thus selecting for patients with relatively severe disease}{\afs22\rtlch \ltrch\loch\fs22
. A central gap }{\afs22\rtlch \ltrch\loch\fs22
(C}{\sub\afs22\rtlch \ltrch\loch\fs22
1}{\afs22\rtlch \ltrch\loch\fs22
 + C}{\sub\afs22\rtlch \ltrch\loch\fs22
2}{\afs22\rtlch \ltrch\loch\fs22
, each 30 days) }{\afs22\rtlch \ltrch\loch\fs22
was excluded to reduce the effects of regression to the mean and errors caused by small inaccuracies in the temporal recording of drugs.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj{\b\afs22\ab\rtlch \ltrch\loch\fs22
Figure }{\b\afs22\ab\rtlch \ltrch\loch\fs22
2}{\b\afs22\ab\rtlch \ltrch\loch\fs22
. (A) }{\afs22\rtlch \ltrch\loch\fs22
One-year and }{\b\afs22\ab\rtlch \ltrch\loch\fs22
(B)}{\afs22\rtlch \ltrch\loch\fs22
 two-year mirror-image analyses, showing the change in admission days per patient per year (}{\afs22\rtlch \ltrch\loch\fs22
admission days }{\afs22\rtlch \ltrch\loch\fs22
per year }{\afs22\rtlch \ltrch\loch\fs22
after }{\afs22\rtlch \ltrch\loch\fs22
drug, minus }{\afs22\rtlch \ltrch\loch\fs22
admission days }{\afs22\rtlch \ltrch\loch\fs22
per year }{\afs22\rtlch \ltrch\loch\fs22
before drug, corrected for overall admission rates; see }{\b\afs22\ab\rtlch \ltrch\loch\fs22
Figure 1}{\afs22\rtlch \ltrch\loch\fs22
 and text). }{{\*\bkmkstart __DdeLink__36495_1236350278}\afs22\rtlch \ltrch\loch\fs22
The number of }{\afs22\rtlch \ltrch\loch\fs22
subjects}{\afs22\rtlch \ltrch\loch\fs22
 contributing to the measurement for each drug is shown in parentheses (}{\i\afs22\ai\rtlch \ltrch\loch\fs22
n}{\afs22\rtlch \ltrch\loch\fs22
)}{{\*\bkmkend __DdeLink__36495_1236350278}\afs22\rtlch \ltrch\loch\fs22
, with mean age in years }{\afs22\rtlch \ltrch\loch\fs22
(at first use of the drug in question, i.e. in the middle of the period considered) }{\afs22\rtlch \ltrch\loch\fs22
and the number of males (M). }{\afs22\rtlch \ltrch\loch\fs22
Points show means and e}{\afs22\rtlch \ltrch\loch\fs22
rror bars show 95% }{\afs22\rtlch \ltrch\loch\fs22
CIs}{\afs22\rtlch \ltrch\loch\fs22
; }{\afs22\rtlch \ltrch\loch\fs22
filled symbols}{\afs22\rtlch \ltrch\loch\fs22
 indicate that the CI excludes zero}{\afs22\rtlch \ltrch\loch\fs22
.}
\par \pard\plain \s30\sl480\slmult1\qj\sb0\sa113\loch\f5\fs22\sl480\slmult1\qj\sb0\sa113{\i0\b\afs22\ab\rtlch \ltrch\loch\fs22
Figure }{\i0\b\afs22\ab\rtlch \ltrch\loch\fs22
3}{\i0\b\afs22\ab\rtlch \ltrch\loch\fs22
. }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
Association of admission rates during a given 6-month calendar period with drug use in the preceding calendar period (}{\i\b0\afs22\ai\ab\rtlch \ltrch\loch\fs22
n}{\i0\b0\afs22\ai0\ab\rtlch \ltrch\loch\fs22
=1,406}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
). The results are expressed as a change in the number of admission days per patient per year (means \u177\'b1 95% }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
CI}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
); }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
filled symbols}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
 indicate that the }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
CI}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
 excludes zero. }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
Interaction terms are expressed with colon notation. The number of patients taking each drug in at least one time period }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
(whether alone or with another drug)}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
 is shown in parentheses (}{\i\b0\afs22\ai\ab\rtlch \ltrch\loch\fs22
n}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
); for interactions, this }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
is}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
 the number of patients who took both drugs }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
during}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
 the same time period, for at least one period. The effect sizes were derived from a regression analysis taking account of all other antipsychotic and antidepressant drugs in the analysis (see text), plus 6-month calendar period number (to account for overall trends over time), }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
age, }{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
time since the first recorded diagnosis of schizophrenia}{\i0\b0\afs22\ab\rtlch \ltrch\loch\fs22
 (in years), and sex.}
\par }